Ascendis Pharma A/S (ASND)

Ascendis Pharma Statistics

Total Valuation

Ascendis Pharma has a market cap or net worth of $9.32 billion. The enterprise value is $9.68 billion.

Market Cap	9.32B
Enterprise Value	9.68B

Important Dates

The last earnings date was Thursday, May 1, 2025, after market close.

Earnings Date	May 1, 2025
Ex-Dividend Date	n/a

Share Statistics

Ascendis Pharma has 60.37 million shares outstanding. The number of shares has increased by 3.88% in one year.

Current Share Class	n/a
Shares Outstanding	60.37M
Shares Change (YoY)	+3.88%
Shares Change (QoQ)	+0.39%
Owned by Insiders (%)	0.78%
Owned by Institutions (%)	82.79%
Float	59.90M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.74
Forward PS	13.18
PB Ratio	-45.45
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	24.29
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.04

Current Ratio	1.04
Quick Ratio	0.67
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-10.08

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-22.39%
Return on Invested Capital (ROIC)	-38.34%
Return on Capital Employed (ROCE)	-189.75%
Revenue Per Employee	$391,848
Profits Per Employee	-$363,125
Employee Count	1,017
Asset Turnover	0.40
Inventory Turnover	0.21

Taxes

In the past 12 months, Ascendis Pharma has paid $3.67 million in taxes.

Income Tax	3.67M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +15.71% in the last 52 weeks. The beta is 0.40, so Ascendis Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.40
52-Week Price Change	+15.71%
50-Day Moving Average	156.45
200-Day Moving Average	139.27
Relative Strength Index (RSI)	45.05
Average Volume (20 Days)	582,774

Short Selling Information

Short Interest	3.90M
Short Previous Month	4.14M
Short % of Shares Out	7.76%
Short % of Float	n/a
Short Ratio (days to cover)	6.88

Income Statement

In the last 12 months, Ascendis Pharma had revenue of $398.51 million and -$369.30 million in losses. Loss per share was -$6.29.

Revenue	398.51M
Gross Profit	339.92M
Operating Income	-360.82M
Pretax Income	-539.03M
Net Income	-369.30M
EBITDA	-355.41M
EBIT	-360.82M
Loss Per Share	-$6.29

Balance Sheet

The company has $559.80 million in cash and $915.77 million in debt, giving a net cash position of -$355.98 million or -$5.90 per share.

Cash & Cash Equivalents	559.80M
Total Debt	915.77M
Net Cash	-355.98M
Net Cash Per Share	-$5.90
Equity (Book Value)	-205.15M
Book Value Per Share	-3.40
Working Capital	38.89M

Cash Flow

In the last 12 months, operating cash flow was -$236.63 million and capital expenditures -$2.09 million, giving a free cash flow of -$244.95 million.

Operating Cash Flow	-236.63M
Capital Expenditures	-2.09M
Free Cash Flow	-244.95M
FCF Per Share	-$4.06

Margins

Gross margin is 85.30%, with operating and profit margins of -90.54% and -92.67%.

Gross Margin	85.30%
Operating Margin	-90.54%
Pretax Margin	-91.75%
Profit Margin	-92.67%
EBITDA Margin	-89.19%
EBIT Margin	-90.54%
FCF Margin	n/a

Dividends & Yields

Ascendis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.88%
Shareholder Yield	-3.88%
Earnings Yield	-3.96%
FCF Yield	-2.63%

Analyst Forecast

The average price target for Ascendis Pharma is $213.88, which is 38.50% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$213.88
Price Target Difference	38.50%
Analyst Consensus	Strong Buy
Analyst Count	16
Revenue Growth Forecast (5Y)	45.47%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ascendis Pharma has an Altman Z-Score of -0.59 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.59
Piotroski F-Score	3